ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 190 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $612,741 | +398.0% | 112,447 | +513.1% | 0.00% | – |
Q2 2023 | $123,052 | -73.1% | 18,342 | -64.6% | 0.00% | -100.0% |
Q1 2023 | $456,959 | +22.2% | 51,754 | +6.1% | 0.00% | 0.0% |
Q4 2022 | $374,000 | +2.5% | 48,778 | -4.8% | 0.00% | 0.0% |
Q3 2022 | $365,000 | -18.2% | 51,226 | -7.1% | 0.00% | 0.0% |
Q2 2022 | $446,000 | -36.2% | 55,138 | +9.3% | 0.00% | 0.0% |
Q1 2022 | $699,000 | -53.2% | 50,467 | -5.3% | 0.00% | -66.7% |
Q4 2021 | $1,495,000 | -15.8% | 53,293 | +1.9% | 0.00% | -25.0% |
Q3 2021 | $1,776,000 | -16.9% | 52,301 | -0.1% | 0.00% | -20.0% |
Q2 2021 | $2,138,000 | +17.1% | 52,337 | +15.4% | 0.01% | +25.0% |
Q1 2021 | $1,826,000 | -27.6% | 45,334 | +6.4% | 0.00% | -42.9% |
Q4 2020 | $2,521,000 | +1.8% | 42,608 | -16.6% | 0.01% | 0.0% |
Q3 2020 | $2,476,000 | +5.2% | 51,115 | +5.0% | 0.01% | -12.5% |
Q2 2020 | $2,354,000 | -53.9% | 48,670 | -73.5% | 0.01% | -61.9% |
Q1 2020 | $5,107,000 | – | 183,780 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
Triatomic Management LP | 102,889 | $560,745 | 0.39% |